LADA (Latent Autoimmune Diabetes in Adults) — commonly nicknamed "type 1.5 diabetes" — is autoimmune diabetes that develops slowly in adulthood. It shares type 1 diabetes' cause (the immune system attacking insulin-producing cells) but progresses gradually like type 2, so it's often misdiagnosed at first. Most people with LADA eventually need insulin, sometimes years after diagnosis.
LADA sits in the space between type 1 and type 2 diabetes. Like type 1, it is caused by the immune system attacking the insulin-producing beta cells of the pancreas. Like type 2, it usually appears in adulthood and progresses slowly enough that, at first, insulin isn't needed and oral medications seem to work. That combination makes LADA one of the more commonly missed diagnoses in adult diabetes care — many people carry a type 2 diagnosis for months or years before antibody testing reveals what's actually happening.
Why "Type 1.5"?
"Type 1.5 diabetes" is a nickname, not an official diagnostic category — you won't find it in the diagnostic manuals. It became popular because LADA doesn't fit neatly into either the type 1 or type 2 box: the underlying disease process (autoimmune beta cell destruction) is the same as type 1, but the pace and initial presentation resemble type 2. Some clinicians instead call it "slow-onset type 1 diabetes," which is arguably a more accurate description of what's actually happening.
How LADA Differs From Type 1 and Type 2
The clearest way to think about it is that LADA shares its cause with type 1 diabetes and its pace with type 2 diabetes:
- Type 1 diabetes — Autoimmune. Rapid beta cell destruction, usually over weeks to months. Typically diagnosed in childhood or young adulthood. Insulin is required from diagnosis.
- Type 2 diabetes — Not autoimmune. Driven by insulin resistance plus relative insulin deficiency. Antibody testing is negative. Often associated with excess weight, though not always. Many people manage for years without insulin.
- LADA — Autoimmune, like type 1 (antibody testing is positive). Slow beta cell decline over months to years, like type 2. Diagnosed in adulthood, often in people who are lean or of normal weight and don't fit the typical type 2 profile. Oral medications may work initially, but most people eventually need insulin as their own insulin production declines.
Who Gets LADA — and Who Should Be Tested
LADA is estimated to account for a meaningful minority of adults initially diagnosed with type 2 diabetes, though exact figures vary by population studied. It's worth considering LADA testing in an adult with an apparent type 2 diagnosis who has any of the following:
- Lean or normal body weight, without the typical features of insulin resistance (metabolic syndrome, strong family history of type 2 diabetes)
- A personal or family history of autoimmune conditions — autoimmune thyroid disease is a particularly relevant one, given how often it travels with LADA
- Blood sugar that responds poorly to, or worsens faster than expected on, standard oral medications
- A relatively young age at diagnosis of what was labeled type 2 diabetes
How LADA Is Diagnosed
The most widely used research definition (from the Immunology of Diabetes Society) requires three things:
- Age 30 or older at diagnosis (a pediatric-onset variant exists but is discussed separately)
- Positive islet autoantibody testing — most often GAD65 (anti-GAD) antibodies, the antibody most strongly associated with LADA; other islet antibodies (IA-2, ZnT8, ICA) may also be checked
- No insulin requirement for at least the first six months after diagnosis
C-peptide testing is used alongside antibody testing — it measures how much insulin the pancreas is still making on its own. In LADA, C-peptide is typically preserved early on but declines over time, sitting somewhere between the near-normal levels seen in early type 2 diabetes and the very low levels seen in established type 1 diabetes.
🔬 Why this diagnosis matters clinically: Getting the label right changes the treatment plan. Sulfonylureas — a common, inexpensive type 2 diabetes medication — push the pancreas to release more insulin, which can accelerate the loss of remaining beta cell function in LADA and are generally best avoided. Recognizing LADA early also means monitoring for the eventual need for insulin, rather than being caught off guard by a sudden decline in control.
Treatment Approach
There's no single protocol used everywhere, but the general approach most endocrinologists take includes:
- Metformin is commonly used early on, the same as in type 2 diabetes, and doesn't affect beta cell function
- GLP-1 receptor agonists are a reasonable option in appropriate patients and may help preserve some beta cell function, though evidence is still evolving
- Sulfonylureas and meglitinides are generally avoided for the reason above
- Insulin is introduced earlier than in typical type 2 diabetes in many treatment approaches, and becomes necessary for essentially everyone with LADA as the disease progresses — the timeline ranges from under a year to well over a decade, largely depending on antibody levels and how much beta cell function remains at diagnosis
- Regular follow-up to track glycemic trends and reassess treatment as insulin production declines, since the pace of that decline varies significantly from person to person
Screening for Other Autoimmune Conditions
Because LADA is autoimmune, people diagnosed with it have a higher-than-average chance of having or developing other autoimmune conditions — autoimmune thyroid disease (Hashimoto's thyroiditis or Graves' disease) in particular. Many endocrinologists check thyroid function and thyroid antibodies as part of the initial workup and periodically afterward.
Key Takeaways
- LADA is autoimmune diabetes that progresses slowly and is diagnosed in adulthood — it shares type 1's cause and type 2's pace
- "Type 1.5 diabetes" is a nickname, not an official diagnosis
- GAD65 antibody testing plus C-peptide is how LADA is distinguished from type 2 diabetes
- Sulfonylureas are generally avoided; most people eventually need insulin
- Screening for autoimmune thyroid disease is a reasonable part of the workup
- An endocrinologist can help confirm the diagnosis and build a treatment plan suited to a progressive condition, rather than one that assumes stability
Our Team Manages Diabetes
All five of our providers manage diabetes and metabolic conditions. Book with any member of our team:
Book an Appointment → or call 832-968-7003